Status:

RECRUITING

Addressing Taste Dysfunction With Miraculin in Head and Neck Cancer Patients Receiving Radiation Therapy

Lead Sponsor:

University of California, San Francisco

Collaborating Sponsors:

Miracle Fruit Farm

Mount Zion Health Fund

Conditions:

Head and Neck Cancer

Taste Dysfunction

Eligibility:

All Genders

18+ years

Phase:

PHASE3

Brief Summary

Patients diagnosed with head and neck cancer who receive radiation therapy with and without chemotherapy develop altered sense of taste due to treatment effect, which typically arises in the second we...

Detailed Description

This is a Phase III, single-center, double-blinded, placebo-controlled, randomized controlled trial. PRIMARY OBJECTIVE: I. To determine if the use of miracle fruit during radiation therapy for head ...

Eligibility Criteria

Inclusion

  • Participants must have documentation of histologically or cytologically confirmed head and neck cancer diagnosis including primary tumors of the following sites: oropharynx, nasopharynx, oral cavity, nasal cavity, paranasal sinus, salivary gland, unknown primary origin in the head and neck, or cutaneous squamous cell carcinoma having had a surgery including neck dissection.
  • Treatment plan includes curative-intent (including post-operative) radiation therapy with or without concurrent chemotherapy
  • Age \>=18 years at screening visit.
  • Eastern Cooperative Oncology Group (ECOG) performance status \<= 2 (Karnofsky \>= 60%)
  • Ability to understand a written informed consent document, and the willingness to sign it

Exclusion

  • Patient-reported pre-existing dysgeusia prior to beginning radiation therapy.
  • Receiving nutrition through tube feeds or intravenously prior to beginning radiation therapy.
  • Inability to complete patient-reported outcomes (PROs) and quality of life questionnaires in English.
  • Known allergy to berries.

Key Trial Info

Start Date :

March 4 2022

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

September 30 2026

Estimated Enrollment :

40 Patients enrolled

Trial Details

Trial ID

NCT05273307

Start Date

March 4 2022

End Date

September 30 2026

Last Update

September 22 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

University of California, San Francisco

San Francisco, California, United States, 94143

Addressing Taste Dysfunction With Miraculin in Head and Neck Cancer Patients Receiving Radiation Therapy | DecenTrialz